Pelizzola D, Bombardieri E, Brocchi A, Cappelli G, Coli A, Federghini M, Giganti M, Gion M, Madeddu G, Maussieri M L
Q J Nucl Med. 1995 Dec;39(4):251-63.
The immunoassay is one of the most sensitive and reliable analytical techniques available in the clinical laboratory. The original label for immunoassays was radioisotopes, and these methods, radioimmunoassay (RIA) and immunoradiometric assay (IRMA) are still the reference methods, because of invulnerability of the radioactive emission with respect to environmental interference. Labels other than radioisotopes have been tested for use in immunoassay to improve the sensitivity and reliability and to avoid some of the disadvantages of radioisotopic techniques. New labels have continued to be developed (Horseradish peroxidase-HPR-, pyrophosphatase, luciferases, pyrodopirazines, europium cryptates, porphirins, phosphors) and new label detection methods have been set up (e.g. chemiluminescence assay, thermometric assay, NADP+ and FADP- based coupled assay). New immunoassay strategies such as simultaneous multianalyte automated test have been developed and the reliability of the assays has in some cases caused division among researchers about the choice between the radioisotopic immunoassay or the non-radioisotopic immunoassay, as considerable effort and investment had been devoted to the search for more sensitive and practicable tests than the classic RIA-IRMA methods. The evolution of immunoassays (Monoclonal Antibodies, non-radioactive tracers, automation) has produced systems which allow a large number of laboratories to determine a great number of analytes with very good practicability. The availability of fully automated systems has generated the opinion that analytical performance of immunoassays can be considered similar to that of many traditional parameters of clinical chemistry. This conclusion seems however too optimistic, in fact data collected from interlaboratory studies demonstrate that problems concerning the analytical reliability of the measurements still remain not completely solved. In the authors' opinion, this opposition between immunological assay based on isotopic or non-isotopic labels is misleading, because each assay (whether it uses isotopic, enzymatic, fluorimetric or luminescent labels) has its own analytical characteristics and performance. For this reason the term "alternative", used to indicate all non-isotopic assays as a unique class of tests, should be abandoned. From a theoretical point of view the choice should not be between isotopic and non isotopic techniques. For each analyte to be tested, it is advisable to use the immunological assay that suits the requirements of the laboratory, irrespective of type of label. From a practical point of view, the choice should be based on the analytical performance and on the characteristics of each assay, on its cost and the type of instrumentation available in the laboratory, and on the experience and the knowledge of the laboratory personnel.
免疫测定是临床实验室中最灵敏、最可靠的分析技术之一。免疫测定最初使用的标记物是放射性同位素,这些方法,即放射免疫测定(RIA)和免疫放射测定(IRMA),仍然是参考方法,因为放射性发射不受环境干扰。除放射性同位素以外的标记物已被用于免疫测定测试,以提高灵敏度和可靠性,并避免放射性同位素技术的一些缺点。新的标记物不断被开发出来(辣根过氧化物酶-HPR-、焦磷酸酶、荧光素酶、吡哆吡嗪、铕穴合物、卟啉、磷光体),并且建立了新的标记物检测方法(例如化学发光测定、温度测定、基于NADP+和FADP-的偶联测定)。诸如同时多分析物自动检测等新的免疫测定策略已经被开发出来,并且在某些情况下,这些测定的可靠性使得研究人员在放射性同位素免疫测定和非放射性同位素免疫测定之间的选择上产生了分歧,因为人们已经投入了大量的精力和资金来寻找比经典的RIA-IRMA方法更灵敏、更实用的检测方法。免疫测定的发展(单克隆抗体、非放射性示踪剂、自动化)产生了一些系统,这些系统使大量实验室能够以很高的实用性测定大量分析物。全自动系统的出现使人们认为免疫测定的分析性能可以被认为与临床化学的许多传统参数相似。然而,这个结论似乎过于乐观,事实上,从实验室间研究收集的数据表明,关于测量分析可靠性的问题仍然没有完全解决。在作者看来,基于同位素或非同位素标记的免疫测定之间的这种对立是误导性的,因为每种测定(无论它使用同位素标记、酶标记、荧光标记还是发光标记)都有其自身的分析特性和性能。因此,用来表示所有非同位素测定为一类独特测试的“替代”一词应该被摒弃。从理论角度来看,选择不应该在同位素技术和非同位素技术之间进行。对于每种要检测的分析物,建议使用适合实验室要求的免疫测定方法,而不考虑标记物的类型。从实际角度来看,选择应该基于每种测定的分析性能、特点、成本、实验室可用的仪器类型,以及实验室人员的经验和知识。